2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald,Nicola Dalbeth,Ted Mikuls,Romina Brignardello‐Petersen,Gordon Guyatt,Aryeh M. Abeles,Allan C. Gelber,Leslie R. Harrold,Dinesh Khanna,Charles King,Gerald Levy,Caryn Libbey,David Mount,Michael H. Pillinger,Ann Rosenthal,Jasvinder A. Singh,James Edward Sims,Benjamin J. Smith,Neil S. Wenger,Sangmee Sharon Bae,Abhijeet Danve,Puja P. Khanna,Seoyoung C. Kim,Aleksander Lenert,Samuel Poon,Anila Qasim,Shiv T. Sehra,Tarun Sudhir Kumar Sharma,Michael Toprover,Marat Turgunbaev,Linan Zeng,Mary Ann Zhang,Amy S. Turner,Tuhina Neogi
DOI: https://doi.org/10.1002/art.41247
2020-05-11
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To provide guidance for the management of gout including indications for and optimal use of urate‐lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Fifty‐seven patient intervention comparator outcome (PICO) questions were developed. This was followed by a systematic literature review including network meta‐analyses with rating of the available evidence according to GRADE methodology, and patient input. A group consensus process was used to compose the final recommendations and grade their strength as strong or conditional.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Forty‐two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of urate‐lowering therapy (ULT) for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first‐line ULT, including in those with moderate‐to‐severe chronic kidney disease (CKD≥3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (≤40 mg/day); a treat‐to‐target management strategy with ULT dose titration guided by serial serum urate (SU) measurements with a SU target of <6 mg/dL. When initiating ULT, concomitant anti‐inflammatory prophylaxis therapy was strongly recommended for a duration of at least 3‐6 months. For management of gout flares, colchicine, NSAIDs, or glucocorticoids (oral, intra‐articular, or intramuscular) were strongly recommended.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Discussion</h3><p>This guideline provides direction for clinicians and patients making decisions on the management of gout, using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences.</p></section>
rheumatology